Cyclo Therapeutics, Inc.
CYTHDelisted Mar 26, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000922247
Cyclo Therapeutics, Inc. was delisted on Mar 26, 2025; its insiders filed their last Form 4 on Mar 3, 2025; 22 institutions reported holding it in 13F filings for Q4 2024, worth $1.33M in total; no superinvestor held it.
13F holders, Q4 2021
Institutional positions in Cyclo Therapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- +2 vs. Q3 2021
- Shares held
- 458.2K
- +127.2K (+38.4%) vs. Q3 2021
- Total value
- $1.71M
- −$526.0K (−23.6%) vs. Q3 2021
- New holders
- 2
- 5 more added
- Sold out
- 0
- 5 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CYTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 22 | $1.33M |
| Q3 2024 | 19 | $1.80M |
| Q2 2024 | 22 | $2.84M |
| Q1 2024 | 22 | $3.01M |
| Q4 2023 | 23 | $2.06M |
| Q3 2023 | 17 | $682.7K |
| Q2 2023 | 14 | $725.2K |
| Q1 2023 | 16 | $820.2K |
| Q4 2022 | 15 | $1.83M |
| Q3 2022 | 12 | $768.0K |
| Q2 2022 | 13 | $794.0K |
| Q1 2022 | 13 | $1.38M |
| Q4 2021 | 15 | $1.71M |
| Q3 2021 | 13 | $2.23M |
| Q2 2021 | 12 | $2.70M |
| Q1 2021 | 9 | $585.0K |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Cyclo Therapeutics, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 254,301 | $948.0K | 0.00% | +82,620+48.1% | Added |
| Renaissance Technologies LLC | 66,300 | $247.0K | 0.00% | +55,818+532.5% | Added |
| Geode Capital Management, LLC | 46,848 | $174.0K | 0.00% | −4,606−9.0% | Reduced |
| State Street Corp | 28,300 | $106.0K | 0.00% | −1,300−4.4% | Reduced |
| Virtu Financial LLC | 22,247 | $83.0K | 0.01% | +22,247 | New |
| BlackRock Inc. | 13,851 | $51.0K | 0.00% | +717+5.5% | Added |
| UBS Group AG | 12,911 | $48.0K | 0.00% | −27,003−67.7% | Reduced |
| Two Sigma Advisers, LP | 10,200 | $38.0K | 0.00% | −2,000−16.4% | Reduced |
| Tower Research Capital LLC (TRC) | 672 | $3.00K | 0.00% | −482−41.8% | Reduced |
| Royal Bank of Canada | 746 | $3.00K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 803 | $3.00K | 0.00% | +300+59.6% | Added |
| Advisor Group Holdings, Inc. | 900 | $3.00K | 0.00% | +900 | New |
| Captrust Financial Advisors | 100 | $0 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 36 | $0 | 0.00% | +1+2.9% | Added |
| IFP Advisors, Inc | 13 | – | – | 00.0% | Unchanged |